PTPN1 and Duchenne muscular dystrophy: Our study identifies PTPN1/2 as potential therapeutic targets for Duchenne muscular dystrophy and suggests the use of PTPN1/2 inhibitors to enhance the myogenic function of DMD muscle stem cells.